A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies.

"data from the cancer genome atlas (tcga) and metabric were retrieved from the cbio cancer genomics portal ( http://cbioportal org ) data from the last updated version of the scan-b dataset was retrieved from mendeley data ( https://data mendeley com/datasets/yzxtxn4nmd ) two other publicly available datasets were obtained from the ncbi gene expression omnibus (geo) repository ( https://www ncbi nlm nih gov ) under the accession numbers gse21653 and gse58812 patients were eligible for inclusion if they exhibited early-stage breast tumors classified as triple-negative by immunohistochemistry and had available gene expression data along with either disease-related survival or overall survival data. data from the cancer genome atlas (tcga) and metabric were retrieved from the cbio cancer genomics portal ( http://cbioportal org ) data from the last updated version of the scan-b dataset was retrieved from mendeley data ( https://data mendeley com/datasets/yzxtxn4nmd ) two other publicly available datasets were obtained from the ncbi gene expression omnibus (geo) repository ( https://www ncbi nlm nih gov ) under the accession numbers gse21653 and gse58812 patients were eligible for inclusion if they exhibited early-stage breast tumors classified as triple-negative by immunohistochemistry and had available gene expression data along with either disease-related survival or overall survival data."

"Declaration of interests B. Conte reports speaker fees from Veracyte and payment for educational events from Medsite and Novartis. A. Prat reports consulting fees from Roche, Pfizer, Novartis, Amgen, BMS, Puma, Oncolytics Biotech, MSD, Guardant Health, Peptomyc and Lilly, lecture fees from Roche, Pfizer, Novartis, Amgen, BMS, Nanostring Technologies and Daiichi Sankyo; patents filed PCT/EP2016/080056, PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369; stockholder and consultant of Reveal Genomics, SL; and institutional financial interests from Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia Innovation Research, SL, Celgene, Astellas and Pfizer. F. Schettini has declared consulting fees from Pfizer, honoraria for lectures from Novartis, Gilead and Daiichy Sankyo, and travel expenses from Novartis and Daiichy Sankyo. O. Martínez-Sáez has declared institutional grants from Roche; personal consulting fees from Roche and Reveal Genomics; honoraria for presentations by Daiichi Sankyo, Pierre Fabre, and Reveal Genomics; and travel expenses by Gilead, Pierre Fabre, Novartis, and MSD. A. Vivancos has declared institutional grants from Bristol Meyers Squibb, Incyte, and Roche; personal consulting fees from Bayer, Bristol Meyers Squibb (BMS); Guardant, Incyte, and Roche; and personal stock options from Reveal Genomics. F. Brasó-Maristany has patents filed: PCT/EP2022/086493, PCT/EP2023/060810, EP23382703 and EP23383369. J. Parker as declared individual and institutional royalties from Veracyte–Prosigna, consulting fees from Bristol Meyers Squibb, Reveal Genomics, and GeneCentric, and holds a patent for breast cancer subtyping. Additionally, he has an equity interest in Reveal Genomics. M. Vidal has declared honoraria for presentations from Novartis, Roche, Pfizer, and Daichii, and travel expenses from Roche and Pfizer. Additionally, she has participated on a Data Safety Monitoring Board or Advisory Board for Novartis and Roche. C. Perou has declared consulting fees and personal stock options from Reveal Genomics. T. Pascual has declared consulting fees from Novartis; honoraria from Novartis, Astra-zeneca, Veracyte, and Argenetics. I. Garcia-Fructuoso has declared honoraria for presentations from Novartis, Daiichi Sankyo, Esteve, GSK; and travel expenses from Novartis, Gilead, Daiichi Sankyo, Lilly, and BMS. L. Paré has declared contract from Reveal Genomics, a HER2DX patent filed (PCT/EP2022/086493), and the TNBCDX patent filed (EP23382703.9). M. Marín-Aguilera has declared contract from Reveal Genomics. P. Villagrasa has declared contract and personal stock options from Reveal Genomics, the HER2DX patent filed (PCT/EP2022/086493), and the DNADX patent filed (EP22382387.3). G. Villacampa has received a speaker's fee from Merck Sharp & Dohme, Pfizer, GlaxoSmithKline and Pierre Fabrer, and received consultant fees from Reveal Genomics. C. Falato is currently employed in AstraZeneca. The remaining authors declare no competing interests."

"B. Conte received funding the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska–Curie grant agreement No 955951. A. Prat received funding from Fundación CRIS contra el cáncer PR_EX_2021-14, Agència de Gestó d'Ajuts Universitaris i de Recerca 2021 SGR 01156, Fundación Fero BECA ONCOXXI21, 10.13039/501100004587Instituto de Salud Carlos III PI22/01017, Asociación Cáncer de Mama Metastásico IV Premios M. Chiara Giorgetti, 10.13039/100001006Breast Cancer Research Foundation BCRF-22-198, Associació Beca Marta Santamaria, and RESCUER, funded by European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement No. 847912. F. Brasó-Maristany received funding from Fundación científica AECC Ayudas Investigador AECC 2021 (INVES21943BRAS) and Fundación Contigo (HIMALAIA). N. Chic received a Beca FSEOM de Estancia de 2 Años para Formación en Investigación Translacional en Centros de Referencia en el Extranjero. L. Paré, M. Marín-Aguilera, and P. Villagrasa González are currently employed in Reveal Genomics."